Boehringer Ingelheim Corporate News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Second Dicerna Hepatic Disease Target Option Exercise
Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target  From Research Collaboration with Dicerna Collaboration seeks to develop novel treatments for chronic liver diseases,  including nonalcoholic steatohepatitis (NASH)  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 4, 2019 Category: Research Source Type: news

Collaboration with Vanderbilt University
Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders  Boehringer Ingelheim Enhances Central Nervous System Disease PipelineVanderbilt Center for Neuroscience Drug Discovery Advances Preclinical Schizophrenia Targets   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 3, 2019 Category: Research Source Type: news

Virtual clinical trial collaboration with Science 37
Boehringer Ingelheim Initiates a Collaborative Partnership with Science 37 to Accelerate Patient Centricity in the Development of Novel Therapies  Boehringer Ingelheim collaborates with Science 37 to accelerate the clinical development of new therapies worldwide  Science 37 ’s technology enables patients to remotely participate in clinical studies, which enables increased patient diversity, study efficiency and speed, while decreasing patient burden (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 3, 2019 Category: Research Source Type: news

Inauguration_facility_children_with_multiple_disabilities
Boehringer Ingelheim and the Muskan Foundation inaugurate facility for children with multiple disabilities  New Facility is ' first-of-its-kind ' at B.J. Wadia Children ’s Hospital, Disability Centre in Mumbai, India Special educational programs will train children with Multiple Disabilities with Visual Impairment (MDVI)  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 17, 2018 Category: Research Source Type: news

A tool to aid in the prevention of African swine fever
Boehringer Ingelheim launches a tool to aid in the prevention of African swine feverASF COMBAT is an online management and biosecurity assessment tool aimed at reducing the African swine fever (ASF) introduction risk levelBoehringer Ingelheim reconfirms its commitment to developing new innovative solutions to address current challenges   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 14, 2018 Category: Research Source Type: news

VARGADO data
Vargatef ® plus docetaxel could be an option after failure of immunotherapy in lung cancerResults from a real-world study1  support a recent update to the ESMO guidelines2 recommending nintedanib (Vargatef®) plus docetaxel following first-line chemotherapy (+/- immunotherapy) in advanced NSCLC of adenocarcinoma histology (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 13, 2018 Category: Research Source Type: news

Over 100 billion birds vaccinated with VAXXITEK
Boehringer Ingelheim vaccinates over 100 billion birds with VAXXITEK ® HVT + IBD since 2006VAXXITEK ® HVT + IBD provides a life-long immunity against Infectious bursal disease and Marek ' s diseaseIt is the first vector vaccine to have been launched on the avian marketVAXXITEK ® HVT + IBD is registered in more than 75 countries  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 13, 2018 Category: Research Source Type: news

Boehringer Ingelheim vaccinates over 100 billion birds with VAXXITEK since 2006
Boehringer Ingelheim vaccinates over 100 billion birds with VAXXITEK ® HVT + IBD since 2006VAXXITEK ® HVT + IBD provides a life-long immunity against Infectious bursal disease and Marek ' s diseaseIt is the first vector vaccine to have been launched on the avian marketVAXXITEK ® HVT + IBD is registered in more than 75 countries  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 12, 2018 Category: Research Source Type: news

Boehringer Ingelheim and GST prepared bring innovation to equine market
Boehringer Ingelheim and Global Stem Cell Technology are prepared to bring groundbreaking innovation to equine marketFirst-ever veterinary stem cell medicine recommended for EU marketing authorisationArti-Cell Forte provides a unique ready-to-use solution for the treatment of equine lamenessBoehringer Ingelheim again demonstrates its commitment to continuous innovation  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 7, 2018 Category: Research Source Type: news

LastMile initiative to address barriers in animal healthcare
Boehringer Ingelheim launches ‘LastMile’ initiative to address major barriers in animal healthcare sector in Sub-Saharan AfricaThe initiative is established by Boehringer Ingelheim and supported by GALVmed (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 3, 2018 Category: Research Source Type: news

Two new claims for Nexgard range in EU and Australia
Boehringer Ingelheim announces two new claims for Nexgard ® and Nexgard Spectra® in the EU and AustraliaBoehringer Ingelheim expands the label claims of its NexGard ® brands for the treatment of two severe skin diseases in dogs in the EU and in AustraliaBy broadening the range, Boehringer Ingelheim contributes to the improvement of dogs ’ health globally (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 23, 2018 Category: Research Source Type: news

Empa ACC Expert Consensus Decision Pathway
American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes and established cardiovascular disease in new Expert Consensus Decision Pathway (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 23, 2018 Category: Research Source Type: news

Survey with Ipsos to gain insights human-animal bond
Boehringer Ingelheim partners with Ipsos to gain insights on human-animal bond in EuropeThe human-animal bond survey assigned to the global Research Institute Ipsos took place in 2017 in five European countries, targeting 3,000 pet ownersThe survey results show a strong positive impact of pet relationship on owners ' well-beingVeterinarians prove to be the contact of choice to provide information on the topic (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 21, 2018 Category: Research Source Type: news

Epizyme_Collaboration
Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies  Boehringer Ingelheim Expands Biomarker-driven Oncology Programs   Alliance Enhances Epizyme ’s Leadership in Oncology Epigenetics  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 15, 2018 Category: Research Source Type: news

Official partner to Cat Care for Life
Boehringer Ingelheim becomes an official partner to CatCareforLifeTheCatCareforLife program is a new worldwide initiative set up by the International Society of Feline MedicineIt aims to encourage cat owners to work with their veterinary clinics to maintain cats in the peak of health through all their life stagesBoehringer Ingelheim is committed to further improving the health and well-being of cats and helping educate veterinarians and cat owners (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 5, 2018 Category: Research Source Type: news